Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Honolulu, Hawaii 96815


Purpose:

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.


Study summary:

To determine mean change in visual acuity at 6 and 12 months


Criteria:

Inclusion Criteria: - Ability to provide written informed consent and comply with study assessments for the full duration of the study - Age greater then and equal 50 years - Patients with active neovascular AMD - Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months - If the patient has bilateral disease and qualifies for the study, both eyes may be included Exclusion Criteria: - Subjects who meet any of the following criteria will be excluded from this study: - Pregnancy or lactation - Premenopausal women not using adequate contraception. - Participation in another simultaneous medical investigation


NCT ID:

NCT00804934


Primary Contact:

Study Chair
Debra L Shimabukuro, RN
Retina Institute of Hawaii


Backup Contact:

N/A


Location Contact:

Honolulu, Hawaii 96815
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.